Evidence map›Paper›PMID 31109153›Full record

ArticleCancers2019

PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Phyu P Aung, Narittee Sukswai, Reza Nejati, Sanam Loghavi, Weina Chen, Carlos A Torres-Cabala, C Cameron Yin, Marina Konopleva, Xiaofeng Zheng, Jing Wang and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Sex-BiasedCancer discovery · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Phyu P AungDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. PAung@mdanderson.org.ORCID 0000-0002-3398-0573
Narittee SukswaiDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. NSukswai@mdanderson.org.ORCID 0000-0001-8513-8153
Reza NejatiDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. reza.nejati@fccc.edu.
Sanam LoghaviDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. sloghavi@mdanderson.org.
Weina ChenDepartment of Pathology and Laboratory Medicine, The University of Texas at Southwestern, Dallas, TX 77030, USA. Weina.Chen@UTSouthwestern.edu.
Carlos A Torres-CabalaDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ctcabala@mdanderson.org.
C Cameron YinDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. cyin@mdanderson.org.
Marina KonoplevaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. mkonople@mdanderson.org.
Xiaofeng ZhengDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. XZheng2@mdanderson.org.
Jing WangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. jingwang@mdanderson.org.
Zhenya TangDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ZTang@mdanderson.org.
L Jeffrey MedeirosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ljmedeiros@mdanderson.org.
Victor G PrietoDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. vprieto@mdanderson.org.
Naveen PemmarajuDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. NPemmaraju@mdanderson.org.
Joseph D KhouryDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. jkhoury@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USThe University of Texas Southwestern Medical Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
National Institutes of Health CA016672NCI NIH HHS P30 CA016672University of Texas MD Anderson Cancer Center Fellowship Research Fund
6 · The paper itself

Abstract

Patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) have poor outcomes despite intensive chemotherapy, underscoring the need for novel therapeutic approaches. The expression status of PD1/PD-L1 in BPDCN remains unknown. We evaluated PD1/PD-L1 by immunohistochemistry and RNAseq expression profiling in a cohort of BPDCN patients. The study group included 28 patients with a median age of 66.8 years (range, 22.8-86.7), 22 men and 6 women. PD-L1 expression was detected by immunohistochemistry in 10/21 (47.6%) cases. PD-L1 expression had a median H-score of 157. The H-score was ≥60 in 7 patients. PD-L1 protein levels (H-score) were proportional to normalized PD-L1 mRNA transcript levels (CD274 mRNA). In addition, high-level PD-L1 expression correlated with higher numbers of PD1-positive cells within BPDCN tumors. There was no correlation between clinicopathologic characteristics and PD-L1 expression status. Similarly, there was no significant difference in overall survival between patients with PD-L1-positive and PD-L1-negative BPDCN (median 12 vs. 23 month, respectively;

Indexed as

immune checkpoint regulationimmunotherapyPD-L1RNA sequencing

Identifiers

PMID31109153
PMCPMC6562447
OpenAlexW2945504457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.